RB Group Plc notes the 9 April 2019 indictment by the US Justice Department in relation to Indivior Plc and Indivior Inc, the pharmaceuticals business which was demerged from RB at the end of 2014
This indictment is not against RB Group Plc or any other group company and we currently have no additional or new information in respect of this matter, apart from what has been publicly issued by the Department of Justice and Indivior Plc.
Investors are referred to previous public statements including Note 19 in our 2018 Annual Report in which we state that at 31 December 2018 the company was recognising a provision (denominated in dollars) of $400m or £313m.
The information contained in Note 19 of our annual report remains our most up to date statement.
For further information, please contact:
SVP, Investor Relations
Director, Investor Relations
Director, External Relations and Government Affairs
+44 (0) 1753 217800
Finsbury (Financial PR)
+44 (0) 20 7251 3801
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
Create your account: sign up and get ahead on news and events
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...